DSc, Ontario Cancer Institute, 610 University Ave, Room 10-415, Toronto, Ontario, Canada.
J Clin Oncol. 2011 Aug 1;29(22):2985-92. doi: 10.1200/JCO.2010.33.7964. Epub 2011 Jun 27.
Percent mammographic density (PMD) is a strong risk factor for breast cancer that changes in response to changes in hormone exposure. We have examined the magnitude of the association of hormone exposure with PMD according to subsequent breast cancer risk.
In three case-control studies, with 1,164 patient cases and 1,155 controls nested in cohorts of women screened with mammography, we examined the association of PMD measured in the baseline mammogram with risk of breast cancer in the following 1 to 8 years (mean, 3 years), according to use of oral contraceptives (OCs) in premenopausal women, menopause, and hormone therapy (HT) in postmenopausal women. All statistical comparisons are adjusted for age and other risk factors.
In premenopausal women who later developed breast cancer (patient cases), PMD was 5.3% greater in past users of OCs than in nonusers (P = .06). In controls, OC users had 2% less density than nonusers (P = .44; test for interaction P = .06). The difference in PMD between premenopausal and postmenopausal women for patient cases was 8.5% (P < .001) and for controls, 3.9% (P = .01; test for interaction P = .03). In postmenopausal women, PMD was 6% greater in patients who used HT than in never users (P < .001). Controls who used HT had 1.6% greater PMD (P = .26) than never users (test for interaction P = .001). Differences in PMD resulted mainly from differences in the dense area of the mammogram.
Differences in PMD associated with differences in hormone exposure were greater in women who later developed breast cancer than in controls in each of the hormone exposures examined.
乳腺密度百分比(PMD)是乳腺癌的一个重要危险因素,其会随激素暴露的变化而变化。我们已经研究了根据随后的乳腺癌风险,激素暴露与 PMD 之间的关联程度。
在三项病例对照研究中,有 1164 名患者病例和 1155 名对照嵌套在乳腺 X 线筛查队列中,我们根据口服避孕药(OC)在绝经前妇女、绝经和激素治疗(HT)在绝经后妇女中的使用情况,在接下来的 1 至 8 年(平均 3 年)中,检查了基线乳腺 X 线片中测量的 PMD 与乳腺癌风险之间的关联。所有统计比较均根据年龄和其他危险因素进行调整。
在后来患有乳腺癌的绝经前妇女(患者病例)中,过去使用 OC 的妇女的 PMD 比未使用者高 5.3%(P=0.06)。在对照中,OC 使用者的密度比未使用者低 2%(P=0.44;交互检验 P=0.06)。患者病例中,绝经前和绝经后妇女之间 PMD 的差异为 8.5%(P<0.001),而在对照中,差异为 3.9%(P=0.01;交互检验 P=0.03)。在绝经后妇女中,使用 HT 的患者的 PMD 比从未使用者高 6%(P<0.001)。从未使用者中,使用 HT 的对照者的 PMD 增加了 1.6%(P=0.26)(交互检验 P=0.001)。PMD 的差异主要源于乳腺 X 线片中致密区域的差异。
在我们研究的每种激素暴露中,与激素暴露差异相关的 PMD 差异在后来发生乳腺癌的妇女中比在对照中更大。